Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Lumos Pharma (LUMO) Stock Price, News & Analysis

Lumos Pharma logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Advanced Chart

Key Stats

Today's Range
$4.34
$4.34
50-Day Range
$4.30
$4.41
52-Week Range
$1.46
$4.58
Volume
N/A
Average Volume
100,335 shs
Market Capitalization
$37.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25
Consensus Rating
Buy

Company Overview

Lumos Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
8th Percentile Overall Score

LUMO MarketRank™: 

Lumos Pharma scored higher than 8% of companies evaluated by MarketBeat, and ranked 925th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Lumos Pharma has received no research coverage in the past 90 days.

  • Read more about Lumos Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Lumos Pharma are expected to grow in the coming year, from ($4.06) to ($1.94) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lumos Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lumos Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lumos Pharma has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for LUMO.
  • Dividend Yield

    Lumos Pharma does not currently pay a dividend.

  • Dividend Growth

    Lumos Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for LUMO.
  • MarketBeat Follows

    1 people have added Lumos Pharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lumos Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    25.40% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 33.99% of the stock of Lumos Pharma is held by institutions.

  • Read more about Lumos Pharma's insider trading history.
Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LUMO Stock News Headlines

Lumos Pharma Completes Merger and Delisting Process
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Lumos Pharma reports sustained growth in PGHD trials
Lumos announces new analyses of data from OraGrowtH210, OraGrowtH212 trials
See More Headlines

LUMO Stock Analysis - Frequently Asked Questions

Lumos Pharma, Inc. (NASDAQ:LUMO) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.34. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $0.50 million. Lumos Pharma had a negative net margin of 1,583.49% and a negative trailing twelve-month return on equity of 233.03%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Pharma investors own include uniQure (QURE), Clean Energy Fuels (CLNE), ACADIA Pharmaceuticals (ACAD), Bicycle Therapeutics (BCYC), Curaleaf (CURLF), Paycom Software (PAYC) and Vale (VALE).

Company Calendar

Last Earnings
11/07/2024
Today
9/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LUMO
CIK
1126234
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$4.25
Low Price Target
$4.25
Potential Upside/Downside
-2.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.29)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-1,583.49%
Pretax Margin
-1,583.49%
Return on Equity
-233.03%
Return on Assets
-129.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.66
Quick Ratio
2.66

Sales & Book Value

Annual Sales
$2.21 million
Price / Sales
17.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
1.26

Miscellaneous

Outstanding Shares
8,649,000
Free Float
6,452,000
Market Cap
$37.54 million
Optionable
Not Optionable
Beta
0.74

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:LUMO) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners